Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Dec 05, 2021 6:30pm
155 Views
Post# 34200553

RE:RE:RE:RE:RE:RE:Options

RE:RE:RE:RE:RE:RE:Options I'm not completely opposed to it for a few reasons, but I can't say it looks great that they changed the timing of when they've done that in the past. I know there's many inputs into these things and I have often thought that the way PL's pryed his old colleagues away from Pfizer is to lure them with contractually agreed upon options as part of their packages. Some may have left behind unvested Pfizer grants or something -- probably not large, but could account for this years. I get that and am ok with it as a tool to hire top quality people who execute the strategy well. Those types should more than pay for the value of the options. Likewise, if Paul couldn't "pay-up" for them and had to compensate them this way, I understand that as well. But that assumes the salary + bonus they expect is at or below their perceived market value or what Pfizer or their other firms paid. The cash comp substitution with options is pretty common, so that's understandable. The alignment is a positive, so that's good too. The change in the timing, however, looks potentially like it could backfire on them if any significant news comes out between now and their normal granting time --someone here said they normally do it in March/April. I haven't looked in to that, but if so, and they do announce something meaningful between now and April, it will look a little cunning on their part. Keep transparency fairly low, only talk dosage, grant options, talk huge dosage, some response, etc... It just won't look that great if that's what happens. But that's only an issue if Mar/Apr is the normal granting period. In the end, the total amount of options is not that great in the grand scheme, at least has a $3+ strike price, and means the news better be that much better than we expect to make up for what smells a tiny bit funny.
palinc2000 wrote: You can also view just the recent here

https://www.canadianinsider.com/node/7?menu_tickersearch=TH+%7C+Theratechnologies

Thao977 wrote: https://www.sedi.ca/sedi/SVTItdSelectIssuer?locale=an_CA Access public filings You Will have all the history




<< Previous
Bullboard Posts
Next >>